Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
Fernando C. Fervenza, Fan Fan Hou, Chuan‐Ming Hao, Gianna M. Kirsztajn et autres
3 citationsNew England Journal of Medicine
Theodore A. Omachi
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
104Publications signalées
4751Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Asthma and respiratory diseasesChronic Obstructive Pulmonary Disease (COPD) ResearchAllergic Rhinitis and SensitizationSystemic Lupus Erythematosus ResearchUrticaria and Related Conditions
Publications récentes
WCN26-7699 B-CELL–TARGETED THERAPY FOR IDIOPATHIC NEPHROTIC SYNDROME: RESULTS OF THE PHASE III, GLOBAL, MULTICENTER INSHORE TRIAL ASSESSING OBINUTUZUMAB VS MYCOPHENOLATE MOFETIL
Julien Hogan, Larry A. Greenbaum, Kandai Nozu, Malgorzata Mizerska-Wasiak et autres
1 citationKidney International Reports
P019 Obinutuzumab demonstrates steroid-sparing effects and consistent benefit in patients with lupus nephritis when using multiple primary endpoint definitions: secondary analysis of the REGENCY trial results
Brad H Rovin, Jay P Garg, Richard Furie, Rachel Jones et autres
0 citationsLara D. Veeken
P021 Obinutuzumab induces histological remission and deep kidney parenchymal B-cell depletion in patients with lupus nephritis: exploratory analyses from the REGENCY trial
Brad H Rovin, Elsa Martins, Cary D. Austin, Harini Raghu et autres
1 citationLara D. Veeken
E006 Kidney-related outcomes with obinutuzumab in patients with active lupus nephritis: a pre-specified exploratory analysis ofthe REGENCY trial
Brad H Rovin, William F. Pendergraft, L Lightstone, Eric Daugas et autres
0 citationsLara D. Veeken
PT2:06 Obinutuzumab induces histological remission and deep kidney parenchymal B-cell depletion in patients with lupus nephritis: exploratory analyses of the phase III regency trial
Brad H Rovin, Elsa Martins, C B Austin, Harini Raghu et autres
0 citations
Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus
Elsa Martins, Vishala Chindalore, X Rebecca Sheng, Aaron Schroeder et autres
1 citationLupus Science & Medicine
L’obinutuzumab démontre un bénéfice constant avec de nombreuses définitions du critère d’évaluation principal d’après les résultats de l’étude REGENCY chez des patients atteints de néphrite lupique active
Z. Amoura, B.H. Rovin, William F. Pendergraft, Liz Lightstone et autres
0 citationsRevue du Rhumatisme
Résultats de l’essai REGENCY évaluant l’efficacité et la tolérance de l’obinutuzumab dans la néphrite lupique active
Z. Amoura, B.H. Rovin, R. Furie, Jay Garg et autres
0 citationsLa Revue de Médecine Interne
#248 Effects of obinutuzumab on urinary renal biomarkers in lupus nephritis: a post hoc exploratory analysis of the phase II nobility study
Juan Manuel Mejía Vilet, H. B. Clarke, Ben Lanza, Veronica G. Anania et autres
0 citationsNephrology Dialysis Transplantation
Beyond Clinical Response in the REGENCY Trial: The Impact of Obinutuzumab on Histologic Remission in Patients with Active Lupus Nephritis
Brad H. Rovin, Valeria Albertón, Elsa Martins, Jay Garg et autres
2 citationsJournal of the American Society of Nephrology
POS0321 KIDNEY-RELATED OUTCOMES WITH OBINUTUZUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A PRE-SPECIFIED EXPLORATORY ANALYSIS OF THE REGENCY STUDY
Brad H. Rovin, W.F. Pendergraft, Liz Lightstone, Éric Daugas et autres
0 citationsAnnals of the Rheumatic Diseases
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.